Iovance Biotherapeutics (IOVA) EPS (Basic) (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly EPS (Basic) of -$188.79 for Q1 2026, up 47.53% year-over-year from -$127.97 in Q1 2025, and down 891.72% quarter-over-quarter from $23.85 in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) EPS (Basic) (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported EPS (Basic) for 17 consecutive years, with -$188.79 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 47.53% year-over-year to -$188.79; the TTM figure through Mar 2026 stood at -$653.3 (up 43.81% YoY), while the FY2025 annual figure was -$868.93, up 32.33% from the prior year.
- EPS (Basic) declined to -$188.79 in Q1 2026 per IOVA's latest filing, from $23.85 in the prior quarter.
- Across five years, EPS (Basic) topped out at $23.85 in Q4 2025 and bottomed at -$758.65 in Q1 2022.
- Historically, EPS (Basic) has averaged -$230.27 across 5 years, with a median of -$250.67 in 2025.
- On a YoY basis, EPS (Basic) climbed as much as 108.79% in 2025 and fell as far as 84680.76% in 2025.
- Iovance Biotherapeutics' EPS (Basic) stood at -$661.31 in 2022, then climbed by 25.18% to -$494.78 in 2023, then soared by 45.2% to -$271.15 in 2024, then jumped by 108.79% to $23.85 in 2025, then sank by 891.72% to -$188.79 in 2026.
- Business Quant data shows IOVA's EPS (Basic) at -$188.79 in Q1 2026, $23.85 in Q4 2025, and -$250.67 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -0.11 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.11 |
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | 0.02 |
| Sep 30, 2025 | -0.25 |
| Jun 30, 2025 | -0.33 |
| Mar 31, 2025 | -0.36 |
| Dec 31, 2024 | -0.27 |
| Sep 30, 2024 | -0.28 |
| Jun 30, 2024 | -0.34 |
| Mar 31, 2024 | -0.42 |
| Dec 31, 2023 | -0.49 |
| Sep 30, 2023 | -0.46 |
| Jun 30, 2023 | -0.47 |
| Mar 31, 2023 | -0.50 |
| Dec 31, 2022 | -0.66 |
| Sep 30, 2022 | -0.63 |
| Jun 30, 2022 | -0.63 |
| Mar 31, 2022 | -0.59 |
| Dec 31, 2021 | -0.65 |
| Sep 30, 2021 | -0.55 |